stockrowAdaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.
- Revenue
- −10.7%
- EPS
- −66.7%
- Free cash flow
- +201.9%
Quarter to September 2026, against a year earlier
Follow ADPT
Alert me
Adaptive Biotechnologies Corporation (ADPT) Gross margin
Adaptive Biotechnologies Corporation's gross margin over the twelve months to 30 September 2026 was 74.2%, down 0.1 percentage points from fiscal 2025 (74.2%). Over the past ten years it has ranged from 55.6% (fiscal 2023) to 77.1% (fiscal 2020); the current reading is higher than 89% of that period. That is above the Diagnostics & Research industry median of 48.3% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 74.2% | 14.52 |
| FY2024 | 59.7% | 4.09 |
| FY2023 | 55.6% | (13.12) |
| FY2022 | 68.8% | 0.69 |
| FY2021 | 68.1% | (9.04) |
| FY2020 | 77.1% | 3.28 |
| FY2019 | 73.8% | 9.15 |
| FY2018 | 64.7% | 5.45 |
| FY2017 | 59.2% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 76.2% | 4.42 |
| Jun 2026 | 71.8% | (1.78) |
| Mar 2026 | 73.6% | (0.98) |
| Dec 2025 | 74.6% | (6.10) |
| 29 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| ADPT Adaptive Biotechnologies Corporation | 74.2% |
| VCYT Veracyte, Inc. compare | 72.0% |
| BLLN BillionToOne, Inc. compare | 71.4% |
| CDNA CareDx, Inc. compare | 71.0% |
| WGS GeneDx Holdings Corp. compare | 69.4% |
| SHC Sotera Health Company compare | 54.6% |
| NEO NeoGenomics, Inc. compare | 44.8% |
| RDNT RadNet, Inc. compare | 11.5% |
| GRAL GRAIL, Inc. compare | 0.00% |
| Diagnostics & Research industry median | 48.3% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on ADPT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement